June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Measured and Predicted Axial Elongation in the MiSight 1 day Clinical Trial – 6 year results
Author Affiliations & Notes
  • Paul Chamberlain
    R&D, Coopervision Inc, Pleasanton, California, United States
  • David Hammond
    R&D, Coopervision Inc, Pleasanton, California, United States
  • Baskar Arumugam
    R&D, Coopervision Inc, Pleasanton, California, United States
  • Mark A Bullimore
    University of Houston, Houston, Texas, United States
  • Footnotes
    Commercial Relationships   Paul Chamberlain, CooperVision (E); David Hammond, CooperVision (E); Baskar Arumugam, CooperVision (E); Mark Bullimore, Alcon (C), Apellis (C), Arctic Vision (C), Asclepix (C), CooperVision (C), CorneaGen (C), Essilor (C), EyeNovia (C), ForSight (C), Genentech (C), Johnson & Johnson Vision (C), Paragon Vision Sciences (C), Presbia (C), Sydnexis (C), Tear Film Innovations (C), Zeiss (C)
  • Footnotes
    Support  Industry Sponsored Study
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 2342. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Paul Chamberlain, David Hammond, Baskar Arumugam, Mark A Bullimore; Measured and Predicted Axial Elongation in the MiSight 1 day Clinical Trial – 6 year results. Invest. Ophthalmol. Vis. Sci. 2021;62(8):2342.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : A 6-year clinical trial randomized subjects to MiSight 1 day (Omafilcon A, dual focus design, CooperVision, Inc.; M1d) or Proclear 1 day (Omafilcon A, single vision, CooperVision, Inc.;P1D) contact lenses for the first three years during which M1d significantly slowed axial elongation Chamberlain et al. (2019). This analysis reports annual axial elongation and overall treatment effects over 6 years using a virtual control group.

Methods : Part 1: 144 myopic children (8-12 years of age) were randomized to wear either M1d or P1d. Part 2: After 3 years, the P1d wearers (n=56) were switched to M1d lenses (M1d-3) while the original treatment group (M1d-6; n=52) continued with M1d. All subjects were followed, unmasked, for an additional 3 years. In the absence of a concurrent control group, a virtual control group was created, based on the axial elongation model of Brennan et al. (AAO 2018). Estimated annual elongation (EAE) was calculated using the age and ethnicity of the P1d control cohort and used to quantify the myopia treatment effect of MiSight over the full 6 years.

Results : EAE for the virtual control group agrees well with the experimental control group during years 1-3. The EAE was 0.619 mm and 0.624 mm respectively, validating the virtual control group and its use for estimating EAE for an untreated control group for the final 3 years. The EAE for the virtual control group growth in years 4 to 6 was 0.395 mm. The year 4-6 total elongation in the M1d-3 and M1d-6 groups were 0.190 mm and 0.184 mm indicating 0.205 mm and 0.211 mm treatment effects. The treatment effect for the M1d-6 group when compared to the virtual control group over the full 6 years revealed a 0.529 mm reduction in axial eye growth (six year cumulative growth of 1.014 (control) – 0.485 mm (treatment).

Conclusions : Using a virtual control group, M1d substantially retards myopia by slowing axial elongation throughout six years of wear. This approach also shows effectiveness in newly treated older subjects in years 4-6.

This is a 2021 ARVO Annual Meeting abstract.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.